Liraglutide - subcutaneous [type 2 diabetes melitus]


Concise Prescribing Info
Indications/Uses
Adjunct to Type 2 DM.
Dosage/Direction for Use
Adult : SC Initial: 0.6 mg/day may increase to 1.2 mg/day. Up to 1.8 mg/day if glycaemic control is not optimal.
Dosage Details
Subcutaneous
Adjunct to Type 2 diabetes mellitus
Adult: Initially, 0.6 mg/day may increase to 1.2 mg/day after 1 wk; and a further increase to 1.8 mg/day after 1 wk if glycaemic control is not optimal.
Renal Impairment
No dosage adjustment needed.
Hepatic Impairment
No dosage adjustment needed.
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC). Patients w/ multiple endocrine neoplasia syndrome type 2 (MEN 2); type 1 DM or diabetic ketoacidosis. Liraglutide is not a substitute for insulin.
Special Precautions
Patients w/ history of pancreatitis or alcoholism, inflammatory bowel disease, diabetic gastroparesis, pre-existing thyroid disease. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Nausea, diarrhoea, vomiting, constipation, headache, dizziness, upper resp tract infection, influenza, sinusitis, nasopharyngitis, UTI, back pain, dehydration. Increased blood calcitonin, goitre, and thyroid neoplasms.
Potentially Fatal: Pancreatitis w/ necrosis; risk of thyroid C-cell tumour.
MonitoringParameters
Monitor for signs and symptoms of pancreatitis (e.g. persistent severe abdominal pain that may radiate to the back, may or may not be accompanied by vomiting.
Overdosage
Symptoms: Severe nausea and vomiting. Management: Symptomatic and supportive treatment.
Drug Interactions
Increased risk of hypoglycaemia when used w/ insulin secretagogues (e.g. sulfonylurea, meglitinide). May affect absorption of concomitantly administered oral drugs due to slow gastric emptying.
Food Interaction
Avoid alcohol as it may cause hypoglycaemia and may increase the risk of pancreatitis.
Action
Description: Liraglutide is an acylated analog of human glucagon-like peptide 1 (GLP-1), an endogenous incretin hormone and acts as a GLP-1 receptor agonist. Activation of GLP-1 receptor stimulates insulin secretion and suppression of glucagon secretion in a glucose-dependent manner. It also delays gastric emptying thus reduces the rate of postprandial glucose present in the circulation. It has lowering effects of fasting, premeal and postprandial glucose; w/ a decrease in haemoglobin A1c by approx 1%.
Pharmacokinetics:
Absorption: Slow absorption after SC inj. Time to peak plasma concentration: 8-12 hr. Bioavailability: Approx 55%.
Distribution: Volume of distribution: Approx 13 L. Plasma protein binding: >98%.
Metabolism: Metabolised endogenously via dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP) enzymes.
Excretion: Via urine (6% as metabolites); faeces (5% as metabolites). Elimination half-life: Approx 13 hr.
Storage
Store between 2-8 °C. Do not freeze. After initial use, it can be stored between 15-30°C for 30 days. Protect from heat and light.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Liraglutide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in